Chronic nodular prurigo (CNPG) is a multifactorial skin disease characterized by itchy papules and nodules, usually resistant to standard treatment and associated with markedly impaired quality of life.
To describe dupilumab effectiveness and tolerability in treating adult patients with CNPG refractory to both topical and systemic therapies.
Retrospective, multicenter study including adult patients affected by CNPG, who were treated with dupilumab for at least 16 weeks.
Twenty-seven CNPG patients showed clinical improvement in terms of skin lesions, itch, sleeplessness, and quality of life. A consistent proportion of patients (24/27; 88.9%) had at least 16-week continuous treatment and achieved Investigator Global Assessment score 1 (11/24; 45.8%). An increased number of patients achieved at least a 2-grade reduction in Investigator Global Assessment score (19/24; 79.2%). Numeric rating scale values for itch and sleeplessness decreased from 8.9 to 2.7 and from 8.2 to 1.7, respectively (P < .001) after 16-week therapy. Ten patients achieved 36 weeks of continuous treatment while maintaining clinical efficacy.
Major limitations included lack of validated assessment tools at the initial data collection, a limited cohort of treated patients, and a short-term observation period.
Dupilumab was proven effective in reducing itch and improving CNPG skin lesions.Le texte complet de cet article est disponible en PDF.
Key words : atopic dermatitis, dupilumab, itch, nodular prurigo
Abbreviations used : CNPG, DLQI, IGA, IL, NRS, SD
| Funding sources: None.
| Conflicts of interest: Dr Chiricozzi served as speaker and advisory board member for Sanofi Genzyme, dupilumab manufacturer. Drs Maurelli, Gori, Argenziano, De Simone, Calabrese, Girolomoni, and Peris have no conflicts of interest to declare.
| IRB approval status: Reviewed and approved by Fondazione Policlinico Universitario Agostino Gemelli IRCCS–Università Cattolica del Sacro Cuore, Prot 24169/19-0040941/19; ID: 2605.
| Reprints not available from the authors.